Healthy Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-Controlled, Single Dose,Dose-escalation,Phase 1a Study of the Safety, Tolerability,Pharmacokinetics and the Potential Immunological Reaction of Recombinant Human Thymosin Beta4 in Chinese Healthy Volunteers
Verified date | May 2020 |
Source | Beijing Northland Biotech. Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to evaluate the safety, tolerance, pharmacokinetics and the potential immunological reaction of single intravenous recombinant human thymosin β4(NL005)or placebo 0.05, 0.25, 0.5, 2, 5, 12.5, 25μg/kg in Chinese healthy volunteers. 54 volunteers will be randomized to receive NL005 or placebo for 7 cohorts,administered iv by iv push on Day 1.
Status | Completed |
Enrollment | 54 |
Est. completion date | June 20, 2018 |
Est. primary completion date | February 20, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Chinese healthy volunteers(male or female). 2. Between 18 and 50 years of age. 3. BMI between 19 and 28 kg/m2. 4. Good health condition, no history of unintentional, liver, kidney, digestive tract, immune system, nervous system, mental and metabolic abnormality, no family history of tumor. 5. Medical history , physical examination, laboratory examinations are normal or not clinically significant abnormalities, and the investigator judges those who are qualified. 6. Voluntarily sign informed consent. Exclusion Criteria: 1. Physical examination, vital signs, ECG or laboratory examinations are abnormal (clinically significant ). 2. Active hepatitis b or c patients, carriers of hepatitis b virus. 3. HIV antibody test positive or syphilis spiral antibody test positive. 4. ADA tests positive. 5. Smoke more than 5 cigarettes a day, had a suspected or proven history of substance abuse, and consumed an average of more than 2 units of alcohol per day for 3 months (1 unit =12 ounces or 360mL beer, 5 ounces or 150mL liquor, 1.5 ounces or 45mL distilled liquor) or had a positive alcohol test. 6. Participated in another trial or used this drug within 3 months before inclusion. 7. Any other drug was used within two weeks before the trial. 8. There is a significant clinical history of allergy, especially for drugs, protein preparations and biological products, especially for rh-tß4 or any of its ingredients. 9. Blood donation or blood loss was equal to or greater than 400 mL within three months prior to the trial. 10. Women who are pregnant or breast-feeding, or who are likely to become pregnant and do not use an acceptable method of contraception, or who have a positive pregnancy test and who do not use effective contraception or whose partner plans to give birth within six months. 11. Unable to tolerate venous blood collection. 12. There is no guarantee that smoking and taking grapefruit juice or any alcoholic and xanthine food and beverage (including chocolate, tea, coffee, cola, etc.) from 48 hours before administration to the last blood sample collection. 13. The investigator judges that the subject is unable to complete the study or otherwise considers that the subject's participation in the study may cause other injury. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Shijitan Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Northland Biotech. Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Tolerated Dose (MTD) . | Determine maximum tolerated dose (MTD) or dose-limiting toxicity (DLT) by comprehensive evaluation of drug safety by adverse event observation, vital signs, physical examination, laboratory examination, electrocardiogram, etc. In this study, DLT was defined as liver, kidney, heart and mental nervous system toxicity of level 2 or above or blood system toxicity of level 3 or above and other systemic adverse events occurred within 14 days after drug administration, and the adverse events were judged to be related to the experimental drug use.If more than 3 (including 3) DLT cases are present in any dose group, the test should be terminated. The previous dose of this dose is considered the maximum tolerated dose (MTD). | Day1 | |
Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.03. | Determine maximum tolerated dose (MTD) or dose-limiting toxicity (DLT) by comprehensive evaluation of drug safety by adverse event observation, vital signs, physical examination, laboratory examination, electrocardiogram, etc. All adverse events were determined according to NCI CTCAE4.03.CTCAE4.03 was classified into grades 1 to 5, in which grade 1 was mild adverse event and grade 5 was death due to adverse event. | Day1 | |
Primary | The Cmax of single ascending doses of rh-Tß4. | Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tß4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , Tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL. | Day 1. | |
Primary | The Tmax of single ascending doses of rh-Tß4. | Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tß4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , Tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL. | Day 1. | |
Primary | The MRT of single ascending doses of rh-Tß4. | Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tß4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , Tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL. | Day 1. | |
Primary | The AUClast of single ascending doses of rh-Tß4. | Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tß4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , Tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL. | Day 1. | |
Primary | The AUC0-inf of single ascending doses of rh-Tß4. | Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tß4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , Tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL. | Day 1. | |
Primary | The t1/2 of single ascending doses of rh-Tß4. | Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tß4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , Tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL. | Day 1. | |
Primary | The VZ of single ascending doses of rh-Tß4. | Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tß4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , Tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL. | Day 1. | |
Primary | The CL of single ascending doses of rh-Tß4. | Approximately 5mL of venous blood was collected at allotted time for the pharmacokinetic study of rh-Tß4 in healthy subjects for the prescribed time.The pharmacokinetic parameters included Cmax , Tmax ,MRT ,AUClast ,AUC0-inf,t1/2 ,VZ , CL. | Day 1. | |
Primary | The potential immunological reaction (antibody formation) of single ascending doses of rh-Tß4. | Approximately 5mL venous blood was collected from subjects before, 14 days after, and 28 days after administration for ADA study of rh-Tß4 in healthy subjects.After the 28th-day follow-up period, subjects who confirm that ADA results are positive should be reexamined every 30 days (±3 days) until the results turn negative or the titer level is stable for two consecutive times. | Day 1?14?28. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |